Inhibition of KMT2D promotes the metabolic transition to aerobic glycolysis by regulating glucose transporter 3 (SLC2A3), increasing the aerobic glycolysis rate and changing the lipid composition of pancreatic cancer cells. This evidence concerns the gene KMT2D and pancreatic neoplasm.